The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma.

Authors

Erin McClure, Lehigh Valley Health NetworkFollow
Michael J Carr
Jonathan S Zager

Publication/Presentation Date

8-1-2020

Abstract

INTRODUCTION: Mitogen-activated protein kinase (MAPK) signal transduction pathway inhibition through the use of agents binding to signal cascade kinases BRAF and MEK has become a key treatment strategy of patients with

AREAS COVERED: Detailed analysis is undertaken of the current data, presenting the efficacy and safety of recently developed therapies targeting BRAF and MEK inhibition in the setting of unresectable melanoma. MAPK signal transduction, translational findings, current phase I, II and III clinical trials, and ongoing studies are explored, including use of MAPK pathway inhibition in the neoadjuvant and adjuvant settings as well as in combination with immunotherapy and other therapies.

EXPERT OPINION: Inhibition of the MAPK pathway significantly improves response, progression-free survival, disease specific survival, and overall survival for patients with

Volume

20

Issue

8

First Page

687

Last Page

701

ISSN

1744-8328

Published In/Presented At

McClure, E., Carr, M. J., & Zager, J. S. (2020). The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma. Expert review of anticancer therapy, 20(8), 687–701. https://doi.org/10.1080/14737140.2020.1796646

Disciplines

Medical Education | Medicine and Health Sciences

PubMedID

32667249

Department(s)

USF-LVHN SELECT Program, USF-LVHN SELECT Program Students

Document Type

Article